MedTrace Logo

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

NCT02081872 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 279000

Last updated 2015-10-08

No results posted yet for this study

Summary

UPGRADE aims to see whether data from Pharmacogenomic Testing (PGx) can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug reactions, hospitalizations and emergency department visits.

The way an individual processes a drug is in part determined by their genes, and there is known to be genetic variation between humans in the way drugs are metabolized. The study of the way genes affect a person's response to drugs is known as "Pharmacogenomics."

Conditions

  • Genetics of Drug Metabolism

Sponsors & Collaborators

  • Companion Dx Reference Lab, LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02081872 on ClinicalTrials.gov